By Colin Kellaher
Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.
Arcturus on Thursday said the designation recognizes the potential of ARCT-2304, a messenger RNA-based vaccine candidate, to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Arcturus, a San Diego medicines and vaccines company, in November launched a Phase 1 clinical study, supported in whole with federal funds from the Department of Health and Human Services.
Outbreaks of avian influenza A H5N1, also known as bird flu, have been decimating U.S. poultry flocks since 2022, and while the federal government currently assesses the risk from H5N1 viruses to the general U.S. population as low, it has committed hundreds of millions of dollars to push development of vaccines for a potential pandemic.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 10, 2025 08:44 ET (12:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.